Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
Abstract
:1. Background
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Caplin, M.E.; Pavel, M.; Ćwikła, J.B.; Phan, A.T.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Wolin, E.M.; Capdevila, J.; Wall, L.; et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: The CLARINET open-label extension study. Endocr. Relat. Cancer 2016, 23, 191–199. [Google Scholar] [CrossRef] [PubMed]
- Rinke, A.; Müller, H.H.; Schade-Brittinger, C.; Klose, K.J.; Barth, P.; Wied, M.; Mayer, C.; Aminossadati, B.; Pape, U.F.; Bläker, M.; et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J. Clin. Oncol. 2009, 27, 4656–4663. [Google Scholar] [CrossRef] [PubMed]
- Pavel, M.; Valle, J.W.; Eriksson, B.; Rinke, A.; Caplin, M.; Chen, J.; Costa, F.; Falkerby, J.; Fazio, N.; Gorbounova, V.; et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy—Biotherapy and Novel Targeted Agents. Neuroendocrinology 2017, 105, 266–280. [Google Scholar] [CrossRef] [PubMed]
- Boyd, A.E.; DeFord, L.L.; Mares, J.E.; Leary, C.C.; Garris, J.L.; Dagohoy, C.G.; Boving, V.G.; Brook, J.P.; Phan, A.; Yao, J.C. Improving the success rate of gluteal intramuscular injections. Pancreas 2013, 42, 878–882. [Google Scholar] [CrossRef] [PubMed]
- Manon, A.; Wolin, E.M.; Chassaing, C.; Bertocchi, L.; Richard, J.; Phan, A.T. Pharmacokinetic (PK) differences between subcutaneous and intramuscular administration of lanreotide: Results from a Phase I study. In Proceedings of the Poster Presented at the 2016 North American Neuroendocrine Tumor Society Symposium, Barcelona, Spain, 9–11 March 2016. [Google Scholar]
- Adelman, D.; Truong Thanh, X.M.; Feuilly, M.; Houchard, A.; Cella, D. Evaluation of Nurse Preferences between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO). Adv. Ther. 2020, 37, 1608–1619. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Strasburger, C.J.; Karavitaki, N.; Störmann, S.; Trainer, P.J.; Kreitschmann-Andermahr, I.; Droste, M.; Korbonits, M.; Feldmann, B.; Zopf, K.; Sanderson, V.F.; et al. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur. J. Endocrinol. 2016, 174, 355–362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Merola, E.; Panzuto, F.; Delle Fave, G. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: A systematic review and meta-analysis. Oncotarget 2017, 8, 46624–46634. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cella, D.; Evans, J.; Feuilly, M.; Neggers, S.; Van Genechten, D.; Herman, J.; Khan, M.S. Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review. Adv. Ther. 2021, 38, 969–993. [Google Scholar] [CrossRef] [PubMed]
- Ryan, P.; McBride, A.; Ray, D.; Pulgar, S.; Ramirez, A.; Elquza, E.; Favaro, J.; Dranitsaris, D. Lanreotide vs. octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis. J. Oncol. Pharm. Pract. 2019, 25, 1425–1433. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ström, T.; Kozlovacki, G.; Myrenfors, P.; Almquist, M. Patient and Nurse Experience of Using Somatostatin Analogues to Treat Gastroenteropancreatic Neuroendocrine Tumors: Results of the Somatostatin Treatment Experience Trial (STREET). Patient Prefer. Adherence 2019, 13, 1799–1807. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Darden, C.; Price, M.; Ray, D.; Goldstein, G.; Goss, D.; Bennett, L.; Garbinsky, D.; Thota, R. Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors. J. Patient Rep. Outcomes 2021, 5, 82. [Google Scholar] [CrossRef] [PubMed]
- Woltering, E.A.; Salvo, V.A.; O’Dorisio, T.M.; Lyons, J., 3rd; Li, G.; Zhou, Y.; Seward, J.R.; Go, V.L.; Vinik, A.I.; Mamikunian, P.; et al. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. Pancreas 2008, 37, 94–100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reubi, J.C.; Waser, B.; Cescato, R.; Gloor, B.; Stettler, C.; Christ, E. Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J. Clin. Endocrinol. Metab. 2010, 95, 2343–2350. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Variables | Patients with Progression in 2019 (no. 16) | Patients with Progression in 2020 (no. 28) | p-Value |
---|---|---|---|
Mean age in years (range) | 62.50 (46–79) | 62.42 (42–79) | 0.56 |
Mean follow-up period in months (range) | 57.88 months (8–144) | 55.18 months (6–152) | 0.724 |
Grading, no. (%) | 0.013 | ||
G1 | 0% | 6 (21.4%) | |
G2 | 12 (75.0%) | 20 (71.4%) | |
G—not established | 4 (25.0%) | 2 (7.1%) | |
Performance status (Karnofsky scale) | 0.79 | ||
≥80 | 14 (87.5%) | 23 (82.1%) | |
<80 | 2 (12.50%) | 5 (17.9%) | |
Distant NET metastases at the beginning of observational, period, no. (%) of patients with: | 0.798 | ||
Liver involvement | 15 (93.8%) | 26 (92.3%) | |
Lymph node involvement | 11 (68.8%) | 17 (60.7%) | |
Bone involvement | 8 (50.0%) | 12 (42.9%) | |
Type of somatostatin analogue | 0.497 | ||
Sandostatin LAR | 6 (37.5%) | 12 (42.9%) | |
Somatuline Autogel | 10 (62.5%) | 16 (57.1%) |
Injection Monitoring System—Card No. |
---|
Phone number to your NET experienced nurse: |
Patient’s first and last name: |
Name of somatostatin analogue: |
Dose of somatostatin analogue: |
Planed date of injection: |
Was the medicine transported in a refrigerator? |
☆ yes ☆ no. |
Was the medicine stored in a refrigerator? |
☆ yes ☆ no. |
Date of planned injection: |
Type of injection: |
☆ Self-injection ☆ Injection given by friend/family member ☆ Injection given by GP-nurse |
Place of injection: |
Problems concerning: |
Drug preparation Injection Side-effects after injection |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sowa-Staszczak, A.; Opalińska, M.; Kurzyńska, A.; Morawiec-Sławek, K.; Gilis-Januszewska, A.; Palen-Tytko, J.; Olearska, H.; Hubalewska-Dydejczyk, A. Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome? Medicina 2021, 57, 1287. https://doi.org/10.3390/medicina57121287
Sowa-Staszczak A, Opalińska M, Kurzyńska A, Morawiec-Sławek K, Gilis-Januszewska A, Palen-Tytko J, Olearska H, Hubalewska-Dydejczyk A. Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome? Medicina. 2021; 57(12):1287. https://doi.org/10.3390/medicina57121287
Chicago/Turabian StyleSowa-Staszczak, Anna, Marta Opalińska, Anna Kurzyńska, Karolina Morawiec-Sławek, Aleksandra Gilis-Januszewska, Joanna Palen-Tytko, Helena Olearska, and Alicja Hubalewska-Dydejczyk. 2021. "Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?" Medicina 57, no. 12: 1287. https://doi.org/10.3390/medicina57121287